Notably, the combination of anagrelide and idarubicin can induce pyroptosis mediated by GSDME, which may serve as a potential therapeutic approach for AML with high PDE3A expression (Yang et al., 2024). The gene discussed is GSDME; the disease is acute myeloid leukemia.